Using advanced imaging to diagnose and predict treatment outcomes for bladder cancer

Application Research of FAPI Positron Emission Tomography(PET)/MRI, 18F-Fluorodeoxyglucose (FDG) PET/MRI, and MRI in the Diagnosis of Muscular Invasive Bladder Cancer and Evaluation of Neoadjuvant Therapy Efficacy

This study is testing new imaging techniques to see if they can better diagnose muscle-invasive bladder cancer and predict how well patients will respond to chemotherapy.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 80 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: First Affiliated Hospital of Fujian Medical University (Academic / other)
• Locations: 1 site (Fuzhou, Fujian)
• Trial ID: NCT06421142 on ClinicalTrials.gov

What this trial studies

This trial investigates the effectiveness of FAPI PET/MRI and FDG PET/MRI imaging techniques in diagnosing muscle-invasive bladder cancer (MIBC) and predicting the success of neoadjuvant chemotherapy. Patients suspected of having MIBC will undergo these imaging examinations, along with standard MRI, to gather clinical and pathological data. The study aims to compare the accuracy of these imaging methods against postoperative results to refine treatment plans for patients. Additionally, it assesses the efficacy of neoadjuvant therapy through follow-up imaging and clinical evaluations.

Who should consider this trial

Good fit: Ideal candidates include patients with suspected or diagnosed muscle-invasive bladder cancer who can undergo the required imaging procedures.

Not a fit: Patients with other concurrent malignancies or those who have received prior neoadjuvant therapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more accurate diagnoses and better treatment strategies for patients with muscle-invasive bladder cancer.

How similar studies have performed: Other studies have shown promising results using advanced imaging techniques for cancer diagnosis and treatment assessment, indicating potential success for this approach.

Eligibility criteria

Inclusion Criteria:

* Inclusion criteria for MIBC diagnostic studies

  1. Patients with suspected muscle-invasive bladder cancer;
  2. Completion of FAPI PET/MRI, FDG PET/MRI and MRI;
  3. Complete clinical laboratory and pathological data.
* Inclusion criteria for MIBC neoadjuvant therapy efficacy evaluation study

  1. Patients diagnosed with muscle invasive bladder cancer;
  2. Completion of FAPI PET/MRI, FDG PET/MRI, and MRI before neoadjuvant therapy;
  3. Complete clinical laboratory and pathological data.

Exclusion Criteria:

* Exclusion criteria for MIBC diagnostic study

  1. Combined with other malignant tumors;
  2. Not receiving surgical treatment;
  3. Receiving neoadjuvant therapy before surgery;
  4. Previous allergy to contrast components or similar components;
  5. Serious organ function abnormalities, such as heart, lung, liver, kidney function serious abnormalities;
  6. Incomplete clinicopathological data
* Exclusion criteria of MIBC neoadjuvant therapy efficacy evaluation study

  1. Combination of other malignant tumors;
  2. FAPI PET/MRI, FDG PET/MRI and MRI were not completed after neoadjuvant therapy;
  3. Prior hypersensitivity to contrast components or similar components;
  4. Serious organ function abnormalities, such as serious abnormalities of heart, lung, liver and kidney function;
  5. Incomplete clinicopathological data.

Where this trial is running

Fuzhou, Fujian

• first hospital affiliated of Fujian medical university — Fuzhou, Fujian, China (Recruiting)

Study contacts

• Study coordinator: Ning Xu, Doctor

Conditions Urinary Bladder Neoplasms; Neoadjuvant Chemotherapy; Neoplasm Staging